Company Profile

Advac LLC
Profile last edited on: 10/29/19      CAGE: 7RVK1      UEI: PJPNK66DNNZ9

Business Identifier: Safer, more effective vaccine for human respiratory syncytial virus (RSV)
Year Founded
2016
First Award
2018
Latest Award
2020
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

873 Misty View Court
Lilburn, GA 30047
   (770) 686-8255
   N/A
   N/A
Location: Single
Congr. District: 04
County: Gwinnett

Public Profile

Advac, LLC is a start-up vaccine research company currently focused on development of a safer, more effective vaccine for human respiratory syncytial virus (RSV) - common respiratory virus that can cause serious complications in infants and older adults. The leading cause of hospitalization among infants in the US, there is no FDA-approved vaccination for RSV. The firm is addressing assessmentof the safety and efficacy of two promising vaccines that would not induce enhanced respiratory disease - one using an inactivated split virus—a virus that is killed with chemicals, then split apart—rather than an inactivated whole virus; the other involving vaccines containing virus-like particles (VLP), which are engineered to resemble viruses but do not contain the viral genome. The latter seems to offer protection against RSV by controlling the replication of the virus in the lungs without causing detectable enhanced respiratory disease. Also being evaluated is a unique adjuvant, a substance that enhances the body’s immune response to the vaccine and improves its effective

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2020 1 NIH $272,223
Project Title: Multi Na-Based Influenza Vaccines
2018 1 NIH $225,000
Project Title: New Rsv Vaccines with Improved Safety and Efficacy

Key People / Management

  Sang-Moo Kang